Use of C2-substituted indan-1-one systems for preparing medicaments for the treatment of obesity

US6946492B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Gerhard Jaehne · Frankfurt, DE
• Volker Krone · Flörsheim, DE
• Martin Bickel · Frankfurt am Main, DE
• Matthias Gossel · Frankfurt am Main, DE

Key dates

• Filing date: Aug 30, 2002
• Grant date: Sep 20, 2005
• Expiry date: Jul 12, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-one systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in methods of embodiments of the invention may include compounds of the formula in which the radicals are as defined, and their physiologically acceptable salts.